Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher remission (MADRS score ≤ 8/HAM‐D score ≤ 7) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission (HAM‐D total score ≤ 8) · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in remission (HAM‐D total score ≤ 8) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher response (≥ 50% reduction in HAM‐D score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher remission (HAM‐D total score ≤ 7) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Change in depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found